Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 301

KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences

Posted by fidest press agency su mercoledì, 22 Mag 2019

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that data has been accepted for presentation at both the C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary and European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal.“We are excited to present more Phase 1 data on KVD900, our oral plasma kallikrein inhibitor in development for on-demand treatment of hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive Officer of KalVista. “Our Phase 2 clinical trial of KVD900 is still expected to have data late this year. We remain committed to providing options for patients to manage their disease with oral medicines.”


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:


Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: